ArticleMedical care research and review : MCRR2022
The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.
Article in Medical care research and review : MCRR, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 33 citations in OpenAlex.
- Buprenorphine prescribing is increasingly delivered by primary care nurse practitioners to Medicaid beneficiaries.Journal of the American Association of Nurse Practitioners · 2026Article
- Aligning training, regulation, and payment policy to advance the behavioral health workforce.Health affairs scholar · 2025Article
- Nurse Practitioner Work Environment and Rural Primary Care for Substance Use.The journal for nurse practitioners : JNP · 2024Article
- Nurse Practitioner Care, Scope of Practice, and End-of-Life Outcomes for Nursing Home Residents With Dementia.JAMA health forum · 2024Article
- Primary care nurse practitioner work environments and emergency department utilization among older adults with substance use disorders in rural areas.Journal of substance use and addiction treatment · 2024Article
- Will the End of the X-Waiver Expand Access to Buprenorphine Treatment? Achieving the Full Potential of the 2023 Consolidated Appropriations Act.Substance abuse · 2023Article
- The role of restrictive scope-of-practice regulations on the delivery of nurse practitioner-delivered home-based primary care.Journal of the American Geriatrics Society · 2023Article
- Nurse prescribing practices across the globe for medication-assisted treatment of the opioid use disorder (MOUD): a scoping review.Harm reduction journal · 2023Article
- Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.JAMA network open · 2023Article
- Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach.Journal of nursing scholarship : an official publication of Sigma Theta Tau International Honor Society of Nursing · 2023Article
- Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods.Journal of substance use and addiction treatment · 2023Article
- State Policies and Buprenorphine Prescribing by Nurse Practitioners and Physician Assistants.Medical care research and review : MCRR · 2022Article
- Buprenorphine treatment episode duration, dosage, and concurrent prescribing of benzodiazepines and opioid analgesics: The effects of Medicaid prior authorization policies.Drug and alcohol dependence · 2022Article
- Buprenorphine Treatment: Advanced Practice Nurses Add Capacity.Health affairs (Project Hope) · 2022Article
- Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.Addiction science & clinical practice · 2022Article
- Laws for expanding access to medications for opioid use disorder: a legal analysis of 16 states & Washington D.C.The American journal of drug and alcohol abuse · 2022Article
- Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.Journal of substance abuse treatment · 2022Article
- Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.JAMA health forum · 2022Article
- Demographic and socioeconomic correlates to buprenorphine access in pharmacies.Journal of the American Pharmacists Association : JAPhAArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
Abstract
This article examines the relationship between federal regulations, state scope-of-practice regulations on nurse practitioners (NPs), and buprenorphine prescribing patterns using pharmacy claims data from Optum's deidentified Clinformatics Data Mart between January 2015 and September 2018. The county-level proportion of patients filling prescriptions written by NPs was low even after the 2016 Comprehensive Addiction and Recovery Act (CARA), 2.7% in states that did not require physician oversight of NPs, and 1.1% in states that did. While analyses in rural counties showed higher rates of buprenorphine prescriptions written by NPs, rates were still considerably low: 3.7% in states with less restrictive regulations and 1.1% in other states. These results indicate that less restrictive scope-of-practice regulations are associated with greater NP prescribing following CARA. The small magnitude of the changes indicates that federal attempts to expand treatment access through CARA have been limited.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.